Liza M. Walsh

Liza M. Walsh is a veteran trial lawyer whose practice centers on complex commercial and intellectual property litigation. She has extensive experience defending major corporations, particularly in the pharmaceutical and life sciences sectors, in high-stakes patent litigation. Her work also covers a range of technologies and industries, including financial services and technology. Public records and professional biographies show a strong tendency to represent defendants; the single tracked case is a defendant-side appearance, consistent with her broader practice of defending large operating companies against infringement claims.

Ms. Walsh is a founding and managing partner of Walsh Pizzi O'Reilly Falanga LLP, which she co-founded in May 2016 after departing from Connell Foley LLP. While at her current firm, her practice has continued its focus on IP litigation. The tracked case lists her affiliation as Connell Foley, which predates the founding of her new firm. Ms. Walsh is frequently involved in cases with parallel proceedings before the Patent Trial and Appeal Board (PTAB), representing clients in district court litigation that is often stayed pending the outcome of inter partes review (IPR). Court filings show her representing parties such as Amgen and LG Electronics in matters involving IPRs.

Among her most notable outcomes, Ms. Walsh was part of the team that represented Pfizer and Takeda in the successful patent litigation concerning the acid-reflux drug Protonix®. That case resulted in a $2.15 billion settlement payment from Teva and Sun Pharmaceuticals after a jury upheld the patent's validity. She was also counsel for EagleView Technologies in a patent dispute over aerial imaging technology where the patents were challenged at the PTAB and the company was ultimately awarded $125 million by a jury.

Admitted to the New Jersey bar in 1985, Ms. Walsh earned her J.D. from Seton Hall University School of Law and a B.S. from Manhattan College.